Find out what Naidong Weng (Janssen Research and Development) has to say about the future of bioanalytical outsourcing, in this expert interview.
Browsing: Mass Spectrometry
“There are, in essence, two schools of thought that I can perceive when discussions occur on the topic of appropriate purity of the laboratory water and various solvents, additives and reagents for any given stage of a quantitative bioanalytical procedure.” Find out more from Robert MacNeill (Envigo) in this editorial column.
SCIEX announces innovations in their ultra low-flow separation and accurate mass analysis, capillary electrophoresis–mass spectrometry (CESI-MS) technology and LGC announces investment plans in new GMP analytical capability.
Researchers from Scripps Research (CA, USA) have recently released a new technology platform designed to allow scientists to more easily quantify molecules from biological samples and make their results public.
The 39th BMSS annual meeting was held from 10–13 September 2018 in Cambridge, UK. In this conference report, Naamah Maundrell explores key highlights from the meeting including significant lectures from international experts.
As part of our Spotlight on the validation of biomarkers, we conducted a survey and compared the results to previous data. Find out more about the key trends, challenges and future potential for biomarker R&D in this informative infographic.
Webinar available to view on demand. Accurate and precise biomarker measurement is critical to identifying diagnostic markers and druggable targets. Learn how quantitative mass spectrometry ensures proper biomarker measurement and characterization.
Time-of-flight secondary ion mass spectrometry utilized in novel technique to map tumor cell signaling
A team from the University of Washington (WA, USA) has demonstrated the use of time-of-flight secondary ion mass spectrometry for mapping tumor cell signals in pancreatic cancer mouse models.
Biomedical research is largely centered on making new discoveries as it relates to human health and disease. The ultimate goal is to understand how human biology works and when and why it goes awry. With a strong foundation on the mechanisms of health and disease, advances in diagnostics and therapeutic interventions can be generated bringing cures to recalcitrant diseases such as cancer and neurodegenerative pathologies.
In this Editorial from Bioanalysis, the authors consider the future for hybrid assays following the US FDA recently issued guidance for hybrid assays. Find out more and access the full article, exclusively for Bioanalysis Zone members.